TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Merck Life Science AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
774,672
|
865,417
|
883,906 |
| Financial expenses |
121
|
0
|
819 |
| Earnings before taxes |
412,875
|
470,773
|
475,135 |
| EBITDA |
393,573
|
444,779
|
472,667 |
| Total assets |
513,989
|
964,627
|
613,179 |
| Current assets |
505,043
|
955,333
|
603,301 |
| Current liabilities |
30,181
|
64,406
|
88,958 |
| Equity capital |
476,702
|
892,974
|
516,998 |
| - share capital |
6,689
|
6,918
|
6,883 |
| Employees (average) |
40
|
48
|
46 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.7%
|
92.6%
|
84.3% |
| Turnover per employee |
19,367
|
18,030
|
19,215 |
| Profit as a percentage of turnover |
53.3%
|
54.4%
|
53.8% |
| Return on assets (ROA) |
80.4%
|
48.8%
|
77.6% |
| Current ratio |
1673.4%
|
1483.3%
|
678.2% |
| Return on equity (ROE) |
86.6%
|
52.7%
|
91.9% |
| Change turnover |
-62,120
|
-23,041
|
262,960 |
| Change turnover % |
-7%
|
-3%
|
42% |
| Chg. No. of employees |
-8
|
2
|
17 |
| Chg. No. of employees % |
-17%
|
4%
|
59% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.